

## NEW RECOGNITIONS TO SUCROSOMIAL IRON®

**Two comprehensive studies published with the collaboration of prestigious universities, a further proof of the efficacy of Sucrosomial Iron®.**

**Pisa, 8 October 2018** – The Sucrosomial Technology®, the [PharmaNutra](#) Group's patent at the basis of the success of the range of SiderAL® products, continues to gain widespread consent in the scientific arena, thanks to two recent publications released last week in equally prestigious international magazines. These publications are the result of the collaboration of PharmaNutra's Scientific Department (Dr. Germano Tarantino, Scientific Director of the Group, and Dr. Elisa Brilli) and major Italian universities with outstanding expertise in the study of the iron metabolism process.

An early article, appeared in the *International Journal of Molecular Sciences*, in collaboration with the University of Pisa (Prof. Ylenia Zambito, Dr. Angela Fabiano), titled "**Ex Vivo and in Vivo Study of Sucrosomial® Iron Intestinal Absorption and Bioavailability**", revealed for the first time new evidence on the absorption kinetics of Sucrosomial Iron®. The study also shows that Sucrosomial Iron® allows higher bioavailability in the bone marrow, where the erythropoietin process takes place.

The second study, "**Sucrosomial® Iron Supplementation in Mice: Effects on Blood Parameters, Hepcidin, and Inflammation**", published in the magazine *Nutrients*, was carried out at the University of Brescia (Prof. Paolo Arosio, Prof. Maura Poli) and the University of Verona (Prof. Domenico Girelli). This publication shows that the use of Sucrosomial Iron® does not have a pro-oxidative effect with respect to conventional ferrous sulfate, thus offering a further interesting indication of the use of the sucrosomial iron®-based Sideral® products.

**Germano Tarantino, PharmaNutra's Scientific Director, so stated:** *"We are extremely satisfied with the publication of these new studies on Sucrosomial Iron®, because, on one hand, they are valuable recognitions, and, on the other hand, they highlight new facts that had never been scientifically validated until now. I am referring to a series of other data on the kinetics of SiderAL®, which are important vantage points in the development of new ways to use the product. The fact that these publications have come about together is not a coincidence, but they are part of a journey started years ago, of which we are finally reaping the benefits. In fact, these are long-term experiments and studies; by the end of the year, other important results will be published, giving further proof of the efficacy of our Sucrosomial Iron®".*

**PharmaNutra S.p.A.**

*Founded and guided by President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003 that develops unique nutraceutical supplements and innovative nutritional devices, taking care of the entire production process, from the proprietary raw materials to the finished product. The efficacy of the products has been demonstrated by numerous clinical studies, 79 of them published with more than 5000 patients treated. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 180 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 70 countries abroad, through 35 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents on sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

<http://www.PharmaNutra.it>

*For more information please contact:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b  
56122 Pisa  
Tel. +39 050 7846500  
Fax +39 050 7846524

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

**Nomad & Specialist**

**CFO SIM S.p.A.**

Via dell'Annunciata  
23/4  
20121 Milan  
Tel. +39 02 303431

[ecm@cfosim.com](mailto:ecm@cfosim.com)

**Press Office**

**Spriano Communication&Partners**

Tel. +39 02 83635708  
Matteo Russo - Cristina Tronconi  
Mob. +39 347 9834881 +39 346  
0477901

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)